Warwick Evidence (Including: Connock, M., Cummins, E., Sutcliffe, P. (Paul), Court, Rachel A., Johnson, Rhona, Grove, Amy L., Kandala, Ngianga-Bakwin, Mohiuddin, Syed and Clarke, Aileen). (2011) Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus. London: National Institute for Health and Clinical Excellence (NICE).

Preview

Text WRAP_Clarke_NICE_Belimumab_56486.pdf - Published Version Download (3875Kb)

Request Changes to record.

Abstract

The manufacturer’s scope encompasses the clinical effectiveness and cost effectiveness of belimumab plus Standard of Care (SoC) relative to SoC alone, for the treatment of adults with active auto-antibody positive Systemic Lupus Erythematosus (SLE) and also for a subgroup of these patients who exhibit signs of high disease activity. According to the manufacturer’s scope and submission the population of greatest interest is the sub-group with high disease activity called the Target population. No subgroup is specified in the National Institute for Health and Clinical Excellence (NICE) scope. The Target population is a subgroup of the proposed licensed population; a decision on the manufacturer’s license application is awaited.

Item Type:	Report
Alternative Title:	Evidence review group report commissioned by the National Health Service Research & Development Programme on behalf of the National Institute for Health and Clinical Evidence
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine
Divisions:	Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) > Warwick Evidence Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Systemic lupus erythematosus -- Treatment, Monoclonal antibodies
Publisher:	National Institute for Health and Clinical Excellence (NICE)
Place of Publication:	London
Official Date:	30 September 2011
Dates:	Date Event 30 September 2011 Published
Number of Pages:	166
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access (Creative Commons)
Date of first compliant deposit:	1 August 2016
Date of first compliant Open Access:	1 August 2016
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
Grant number:	10/73/01 (NIHR HTA)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item

Downloads